Evidence map›Paper›PMID 26864031›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2016

Mucosal Humoral Immune Response to SIVmac239∆nef Vaccination and Vaginal Challenge.

Ming Zeng, Anthony J Smith, Liang Shang, Stephen W Wietgrefe, James E Voss, John V Carlis, Qingsheng Li, Michael Piatak, Jeffrey D Lifson, R Paul Johnson and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 13 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Ming ZengDepartment of Microbiology and Immunology, Medical School, University of Minnesota, Minneapolis, MN 55455;
Anthony J SmithDepartment of Microbiology and Immunology, Medical School, University of Minnesota, Minneapolis, MN 55455;
Liang ShangDepartment of Microbiology and Immunology, Medical School, University of Minnesota, Minneapolis, MN 55455;
Stephen W WietgrefeDepartment of Microbiology and Immunology, Medical School, University of Minnesota, Minneapolis, MN 55455;
James E VossDepartment of Immunology and Microbial Science, International AIDS Vaccine Initiative Neutralizing Antibody Center, Center for HIV/AIDS Vaccine Immunology and Immunogen Design, The Scripps Research Institute, La Jolla, CA 92037;
John V CarlisDepartment of Computer Science and Engineering, College of Science and Engineering, University of Minnesota, Minneapolis, MN 55455;
Qingsheng LiDepartment of Microbiology and Immunology, Medical School, University of Minnesota, Minneapolis, MN 55455;
Michael PiatakAIDS and Cancer Virus Program, Science Applications International Corporation-Frederick, Inc., National Cancer Institute, Frederick, MD 21702;
Jeffrey D LifsonAIDS and Cancer Virus Program, Science Applications International Corporation-Frederick, Inc., National Cancer Institute, Frederick, MD 21702;
R Paul JohnsonNew England Primate Research Center, Harvard Medical School, Southborough, MA, 01772; and Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139.
Ashley T HaaseDepartment of Microbiology and Immunology, Medical School, University of Minnesota, Minneapolis, MN 55455; haase001@umn.edu.
University of Minnesota Medical Center · USScience Applications International Corporation (United States) · USInternational AIDS Vaccine Initiative · USNew England Biolabs (United States) · USUniversity of Minnesota · US

Funding

VirologyU19AI095985 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI BAROUCH, DAN H., JOHNSON, R. PAUL · 2011 to 2015
$35.9M
Pathology and Veterinary Service CoreP01AI071306 · NIAID · HARVARD MEDICAL SCHOOL · PI JOHNSON, R. PAUL · 2007 to 2011
$18.3M
Nebraska Center for VirologyP30GM103509 · NIGMS · UNIVERSITY OF NEBRASKA LINCOLN · PI WOOD, CHARLES · 2012 to 2014
$3.3M
Vaccine Design to Concentrate Protective Antibodies at the Mucosal BorderR01AI102625 · NIAID · UNIVERSITY OF MINNESOTA · PI HAASE, ASHLEY T. · 2012 to 2015
$3.1M
CCR NIH HHS HHSN261200800001CNCI NIH HHS HHSN261200800001ENIAID NIH HHS AI071306NIAID NIH HHS P01 AI071306NIAID NIH HHS R01 AI102625NIAID NIH HHS U19 AI095985NIGMS NIH HHS P30 GM103509NIH HHS OD01110
6 · The paper itself

Abstract

Live attenuated vaccines such as SIV with a deleted nef gene have provided the most robust protection against subsequent vaginal challenge with wild-type (WT) SIV in the SIV-rhesus macaque model of HIV-1 transmission to women. Hence, identifying correlates of this protection could enable design of an effective HIV-1 vaccine. One such prechallenge correlate of protection from vaginal challenge has recently been identified as a system with three components: 1) IgG Abs reacting with the viral envelope glycoprotein trimeric gp41; 2) produced by plasma cells in the submucosa and ectopic tertiary lymphoid follicles in the ectocervix and vagina; and 3) concentrated on the path of virus entry by the neonatal FcR in the overlying epithelium. We now examine the mucosal production of the Ab component of this system after vaginal challenge. We show that vaginal challenge immediately elicits striking increases in plasma cells not only in the female reproductive tract but also at other mucosal sites, and that these increases correlate with low but persistent replication at mucosal sites. We describe vaginal ectopic follicles that are structurally and functionally organized similar to follicles in secondary lymphoid organs, and we provide inferential evidence for a key role of the female reproductive tract epithelium in facilitating Ab production, affinity maturation, and class switch recombination. Vaccination thus accesses an epithelial-immune system axis in the female reproductive tract to respond to exposure to mucosal pathogens. Designing strategies to mimic this system could advance development of an effective HIV-1 vaccine.

Indexed as

AIDS VaccinesAnimalsAntibodies, ViralEpitheliumFemaleHistocompatibility Antigens Class IHIV-1HIV Envelope Protein gp41HIV InfectionsHumansImmunity, HumoralImmunity, MucosalImmunizationMacaca mulattaReceptors, FcSimian Acquired Immunodeficiency SyndromeAIDS VaccinesAntibodies, ViralFc receptor, neonatalHistocompatibility Antigens Class IHIV Envelope Protein gp41Receptors, FcVaccines, Attenuated

Identifiers

PMID26864031
PMCPMC4779663
OpenAlexW2284569189

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.